GlassScriptPhysician profile
Stephen Walter Hardeman
NPI 1427052992
$3,302.07
in general payments reported to CMS, 2019-2025
40 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $150 · 2021: $203 · 2022: $382 · 2023: $827 · 2024: $1,162 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.10 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.14 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $400.20 | 2023-2024 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $323.43 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $173.85 | 2019-2025 | Xtandi, Myrbetriq |
| Olympus America INC. | $139.32 | 2024 | Itind System |
| Janssen Biotech, INC. | $138.69 | 2019-2024 | Erleada, Balversa |
| Allergan, INC. | $98.31 | 2019-2021 | |
| Teleflex LLC | $82.76 | 2023 | Urolift |
| Pfizer INC. | $81.18 | 2022-2025 | |
| Bluewind Medical | $78.12 | 2024 | Revi |
| Merck Sharp & Dohme LLC | $76.92 | 2020-2024 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $69.53 | 2024-2025 | |
| Convatec INC. | $56.65 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $51.79 | 2024 | |
| Innovation Technologies INC | $48.90 | 2024 | Irrisept |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hardeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.